Search

everythinglearnresearchcommunity

for

Search:↓

The user stopped using oral minoxidil due to shedding and is continuing with oral finasteride and hair vitamins. They are advised that shedding is temporary and to maintain finasteride use, with examples of others successfully managing hair loss with similar treatments.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

Dutasteride capsules should not be bitten or opened due to their foul taste and potential caustic effects. Users shared experiences of accidentally biting capsules and the unpleasant taste, with some suggesting swallowing techniques to avoid this.

The user added topical minoxidil to their finasteride regimen, resulting in healthier hair and some regrowth, especially after quitting nicotine. They experienced minimal shedding and noted improvements in hairline density, finding the treatment mostly preventative.

The user shared a 4-5 month update on using finasteride, minoxidil, vitamins, oiling, and microneedling for hair loss. They reported improved hair density and confidence but experienced unwanted hair growth, thin hair, itching, and a flaky scalp.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

A 24-year-old male shares his 5-month progress using 1mg finasteride daily, biotin supplements, multivitamins, 3ml minoxidil daily, and derma rolling twice a week. A user inquires about hair shedding and the type of minoxidil used.

User ItchyRaccoon experienced significant hair loss reduction using Eucapil after trying low-dose topical finasteride with no results. Some replies mention that shed hair counts are not reliable indicators of hair loss progression or regression.

Hair loss treatments including Minoxidil, Finasteride and RU58841; with a focus on Pyrilutamide could potentially be used as an effective treatment.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.